EXTRA-STRENGTH AIM
LOE Approachingsodium monofluorophosphate
NDADENTALGEL
Approved
Aug 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXTRA-STRENGTH AIM is a dental gel formulation containing sodium monofluorophosphate, a fluoride compound designed to strengthen tooth enamel and prevent dental caries. Applied topically to teeth, it delivers fluoride ions that remineralize enamel and inhibit bacterial acid production. This product targets consumers seeking enhanced cavity prevention and oral health maintenance.
LOE Approaching
As an aging product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on lifecycle management and cost optimization rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice
Started May 2012
100 enrolled
Caries
Career Relevance
Working on EXTRA-STRENGTH AIM offers limited career growth due to its LOE-approaching status and zero linked job openings; roles available focus on defensive market share protection and operational efficiency rather than innovation. This is a "maintenance" assignment suitable for early-career professionals seeking stability or mid-career specialists managing decline, but not ideal for those seeking high-visibility growth opportunities.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.